BOSTON SCIENTIFIC CORP

Boston Scientific’s WATCHMAN FLX and EKOS trials confirm breakthrough safety, boosting market confidence amid active trading and a pending class‑action lawsuit.

Boston Scientific (BSX) sees bullish analyst coverage, institutional buys, and steady but declining prices—insightful for investors targeting health‑care equipment growth.

Boston Scientific Corp. has reported a strong third-quarter performance, exceeding analyst expectations and boosting its annual profit forecast, driven by surging demand for its heart-device portfolio.

Boston Scientific Corp has reported a 22.8% increase in net sales to $5.061 billion, exceeding expectations and setting a new benchmark for the company’s financial performance.

Boston Scientific Corp reported strong Q1 2025 earnings, exceeding market expectations and prompting an upgrade in its full-year guidance, despite facing external challenges.